As scientific innovation in molecular imaging explodes, experts believe the big payoff will be in clinical, rather than research, applications. But absent validating clinical data, businesses remain hesitant to jump into the field.

Anti-angiogenesis as a treatment for cancer was hardly a new concept, even in 1998 when a New York Times article first put Judah Folkman's work on the public map. Although the hype has died away, the industrial machine of anti-angiogenesis has continued to roll on--as indicated by the start-up activity we describe in the following profiles.